Search

Displaying results 651 - 660 of 5383 in total
  1. Drug

    Zinc dibutyldithiocarbamate

    go.drugbank.com/drugs/DB14194
    Approved

    Zinc dibutyldithiocarbamate is a dermatological sensitizer and allergen. Sensitivity to zinc dibutyldithiocarbamate may be identified with a clinical patch test.

    Mixtures: Test Thin-Layer Rapid Use Patch TestCategories: Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use
  2. Drug

    Glutethimide

    go.drugbank.com/drugs/DB01437
    ApprovedIllicit

    Its use has been largely superseded by other drugs.

  3. Drug

    Eladocagene exuparvovec

    go.drugbank.com/drugs/DB16780
    ApprovedInvestigational

    [A253687] It was subsequently approved by the FDA in November 2024.[L51898,L51893] … Eladocagene exuparvovec is infused directly into the brain (putamen) by bilateral intraputaminal infusion in one surgical session.

  4. Drug

    Pravastatin

    go.drugbank.com/drugs/DB00175
    ApprovedInvestigational

    [T274] This drug was developed by Sankyo Co. Ltd.; however, the first approved pravastatin product was developed by Bristol Myers Squibb and FDA approved in 1991. … The manufacturing process is followed by the hydrolysis of the lactone group and the biological hydroxylation with _Streptomyces carbophilus_ to introduce the allylic 6-alcohol group.[T239]

    Mixtures: Pal-pravastatin-asa, Pal-pravastatin-asa
  5. Drug

    Acemetacin

    go.drugbank.com/drugs/DB13783
    ApprovedInvestigational

    [T50] It was developed by E. … Merck and Company in Germany as an attempt to provide a safer drug but other than the amelioration on the gastrointestinal effects, the metabolism of acetamicin led to the formation of indomethacin and

  6. Drug

    Bismuth subnitrate

    go.drugbank.com/drugs/DB13209
    ApprovedWithdrawn

    The use of bismuth substrate as an active ingredient in over-the-counter antacids is approved by the FDA.

  7. Drug

    Relacorilant

    go.drugbank.com/drugs/DB14976
    ApprovedInvestigational

    [L56089] Relacorilant was approved by the US FDA on March 25, 2026, for use in combination with [paclitaxel] in patients with certain platinum-resistant cancers.[L56093,L56089] … [A275455,L56096] By competitively blocking the glucocorticoid receptor, relacorilant prevents cortisol from activating anti-apoptotic survival pathways, thereby restoring the efficacy of cytotoxic therapies

  8. Drug

    Afatinib

    go.drugbank.com/drugs/DB08916
    ApprovedInvestigational

    by an FDA-approved test [L2939]. … For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected

  9. Drug

    Hydroxyprogesterone caproate

    go.drugbank.com/drugs/DB06789
    Approved

    Hydroxyprogesterone caproate was previously marketed under the trade name Delalutin by Squibb, which was approved by the U.S.

    Categories: Hormonal Contraceptives for Systemic Use
  10. Drug

    Minoxidil

    go.drugbank.com/drugs/DB00350
    ApprovedInvestigational

    A potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure.

    Products: Minoxidil Topical Solution USP, 2%, GOOD GUY Mens Hair Regrowth Treatment